| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
The administration of Goreisan elevated the levels of secondary bile acids in the feces of mice. However, the assessments for the intestinal bacteria and their gene analysis were not successful to confirm the activation of bacterial synthesis of secondary bile acids by Goreisan. The changes in fecal bile acids by Goreisan were not associated with the changes in the levels of gene transcripts regulated by bile acid receptor activation in the colon. The administration of Boiogito increased the levels of deoxycholic acid but decreased those of alpha-muricholic acids in the feces of mice, suggesting that Boiogito decreased bile acid hydrophobicity in the intestinal lumen and attenuated farnesoid X receptor (FXR)-mediated responses in the intestine. Boiogito elevated the fecal levels of cholesterol and reduced the levels of hepatic lipids, which were supposed to be due to the attenuations of cholesterol solubilization in the intestinal lumen and FXR activation in the intestine.
|
